# Activ Surgical

> Activ Surgical develops surgical imaging hardware and software that add real-time physiological information to compatible operating-room systems. Its ActivSight Intelligent Light module combines dye-free laser speckle perfusion imaging with indocyanine green fluorescence, helping surgeons assess blood flow and critical structures during minimally invasive procedures. The company sells access through a subscription model and is developing AI-assisted visualization on its ActivEdge platform.

- **Founded:** 2017
- **Headquarters:** Boston, United States
- **Founders:** Peter C. W. Kim (Co-founder; inventor; surgeon and scientific leader), Seth Teicher (Co-founder (listed by Crunchbase))
- **Products:** ActivSight Intelligent Light, ActivPerfusion Mode, ActivICG Mode, ActivInsights, ActivEdge
- **Notable:** FDA 510(k) clearance for ActivSight (K203550), April 2021., First-in-human safety and feasibility procedures announced in November 2021., CE mark announced December 2022.

## Products & services

- **ActivSight Intelligent Light** — Modular intraoperative imaging system combining laser speckle and ICG fluorescence visualization; received FDA 510(k) clearance in 2021. Compatibility must be checked for the intended equipment.
- **ActivPerfusion Mode** — Dye-free laser speckle contrast imaging of tissue blood flow with real-time visual overlays.
- **ActivICG Mode** — Fluorescence imaging using indocyanine green for perfusion and indicated critical-structure visualization.
- **ActivInsights** — AR-based software suite announced with ActivSight as a technology-as-a-service bundle.
- **ActivEdge** — Underlying surgical intelligence platform and development framework for sensing, visualization, AI and machine learning. The broader autonomous-surgery vision should not be confused with the marketed imaging module.
- **Colorectal AI visualization mode** — Announced first AI-enabled case in January 2023; focuses the perfusion overlay on colon tissue and suppresses non-bowel background signals. The announcement alone does not establish broad commercial availability.

## Achievements

- FDA 510(k) clearance for ActivSight (K203550), April 2021.
- First-in-human safety and feasibility procedures announced in November 2021.
- CE mark announced December 2022.
- First AI-enabled ActivSight case announced January 2023.
- An Ohio State forty-patient study reported advanced visualization changed intraoperative decisions in 17.5% of cases; it was not powered to detect differences in leak rates.
- First announced international procedure performed at Abdali Hospital on December 24, 2023.
- Peer-reviewed clinical and preclinical publications on laser speckle imaging and perfusion quantification.
- Investor LRVHealth reports more than 1,500 surgical cases on its undated portfolio page, verified October 5, 2026.

## Latest updates

- **2024-07** — A study published online July 29 in Surgical Endoscopy evaluated dye-free quantified perfusion in a porcine model; the authors called for histologic and human validation.
- **2024-06** — The forty-patient Ohio State colorectal study appeared in Diseases of the Colon & Rectum; it documented decision changes but was not powered for leak-rate differences.
- **2024-01** — Company announced its first international ActivSight procedure, performed the previous December at Abdali Hospital in Jordan.

## Links

- Website: https://www.activsurgical.com/
- LinkedIn: https://www.linkedin.com/company/activ-surgical/
- Twitter/X: https://twitter.com/ActivSurgical

---

Profile page: https://yespress.io/activ-surgical
Published by YesPress — https://yespress.io
Last updated: 2026-10-05